Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Following Complete or Partial Response to Platinum Based Chemotherapy Clear all

Approved For Marketing No phase listed Expanded access

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT03079687

View directory record Official record

Conditions: Ovarian Cancer
Interventions: Olaparib tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Roseville, California + 10 more

Source: ClinicalTrials.gov public record

Updated Oct 24, 2017 · Synced May 22, 2026, 3:53 AM EDT

Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676

View directory record Official record

Conditions: Platinum Sensitive Relapsed Ovarian Cancer
Interventions: OLAPARIB, PLACEBO; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years · Female only

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more

Source: ClinicalTrials.gov public record

Updated May 1, 2016 · Synced May 22, 2026, 3:53 AM EDT

Active, not recruiting Phase 3 Interventional Results available

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353

View directory record Official record

Conditions: Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Olaparib 300mg tablets, Placebo to match olaparib 300mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only

Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more

Source: ClinicalTrials.gov public record

Updated Aug 2, 2025 · Synced May 22, 2026, 3:53 AM EDT